Syngene International: Independent Director Kush Parmar Resigns
NiveshIQ
NSE: SYNGENE · Healthcare
Syngene International Ltd.
₹414.25▲ ₹5.10 (+1.25%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SYNGENE. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Syngene International Ltd.
Syngene International Limited is a leading contract research and manufacturing company in the Indian healthcare sector. The company provides a range of services including discovery chemistry, discovery biology, and chemical, formulation, analytical, and clinical development services. Its key revenue drivers are lead generation, preclinical development, API, and drug product development services. Syngene operates in India, the United States of America, Europe, and internationally, with a strong presence in the global pharmaceutical market. In its recent FY26 results, the company reported a revenue rise, although the earnings were lackluster. Syngene's competitive position is strengthened by its expertise in drug discovery and development services, and its ability to provide end-to-end solut
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹3,489 Cr +96.00% | ₹3,643 Cr +4.40% | ₹3,739 Cr +2.60% |
| EBITDA Margin | 29.09% | 28.63% | 26.46% |
| Net Profit | ₹510.00 Cr +76.50% | ₹496.00 Cr -2.70% | ₹317.00 Cr -36.10% |
| EPS | ₹12.68 | ₹12.33 | ₹7.87 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
SYNGENE: Q1 FY27 saw a consolidated net loss amid revenue decline, forex losses, and exceptional costs
Syngene appoints Sreenivasulu Bandaru as Head of Chemical Development
🔒
+ 3 more stories about Syngene International Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q4FY26 results: revenue ₹1,036 Cr, PAT ₹148 Cr, EPS ₹3.67, EBITDA margin 31.4%. Growth context: revenue QoQ +13.0%, PAT QoQ +886.7%. Street verdict: beat, revenue surprise +1.2%, PAT surprise -0.8%.
Recent corporate activity highlights geographic expansion and international growth as the primary near-term growth lever...
Forward consensus estimates for the next FY will be the key financial watchpoint as the current year plays out....
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SYNGENE
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SYNGENE alongside your other holdings
Unlock full SYNGENE research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Syngene International Ltd.?
NiveshIQ detects active intelligence signals for Syngene International Ltd. (SYNGENE) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Syngene International Ltd.?
Syngene International Ltd. operates in the Healthcare sector with a market capitalisation of ₹1,851,528.8L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.